TCGA-A8-A06X-01A-21R-A00Z-07
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
- overall_survival_months
- 31
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.550
- INTERFERON_GAMMA_RESPONSE+0.430
- E2F_TARGETS+0.420
- OXIDATIVE_PHOSPHORYLATION+0.410
- MYC_TARGETS_V1+0.400
- G2M_CHECKPOINT+0.390
- UNFOLDED_PROTEIN_RESPONSE+0.380
- MYC_TARGETS_V2+0.370
- MTORC1_SIGNALING+0.320
- MITOTIC_SPINDLE+0.260
Top 10 suppressed
- ANGIOGENESIS-0.430
- WNT_BETA_CATENIN_SIGNALING-0.350
- HEDGEHOG_SIGNALING-0.320
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.290
- KRAS_SIGNALING_UP-0.290
- MYOGENESIS-0.250
- KRAS_SIGNALING_DN-0.180
- UV_RESPONSE_DN-0.180
- ANDROGEN_RESPONSE-0.150
- APICAL_JUNCTION-0.140
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | ddd65fce-1a39-415c-9114-7a9c8e9b266c | — | — | 0.882 |
| 2 | SRR8518289 | — | E | 0.869 |
| 3 | R371 | — | — | 0.867 |
| 4 | SRR11296765 | — | — | 0.867 |
| 5 | MNG277 | — | — | 0.863 |
| 6 | TCGA-HD-7832-01A-11R-2132-07 | — | — | 0.859 |
| 7 | 81b828aa-cb06-4790-ba3e-efaa39f4eeef | — | — | 0.858 |
| 8 | TCGA-52-7812-01A-11R-2125-07 | — | cohortA1 | 0.854 |
| 9 | SRR17866821 | — | — | 0.846 |
| 10 | ERR2278852 | — | — | 0.845 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 30 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.550 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.430 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.420 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.410 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.400 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.390 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.380 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.370 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.320 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.260 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.230 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.190 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.180 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.180 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.160 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.130 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.120 | Inavolisib | — uncovered |
| APOPTOSIS | 0.110 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.110 | Idelalisib | — uncovered |
| PEROXISOME | 0.110 | Idelalisib | — uncovered |